Logo image of IBS.LS

IBERSOL SGPS SA (IBS.LS) Stock Fundamental Analysis

Europe - ELI:IBS - PTIBS0AM0008 - Common Stock

10.1 EUR
0 (0%)
Last: 10/3/2025, 7:00:00 PM
Fundamental Rating

4

Taking everything into account, IBS scores 4 out of 10 in our fundamental rating. IBS was compared to 52 industry peers in the Hotels, Restaurants & Leisure industry. While IBS is still in line with the averages on profitability rating, there are concerns on its financial health. IBS is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

IBS had positive earnings in the past year.
IBS had a positive operating cash flow in the past year.
Of the past 5 years IBS 4 years were profitable.
Each year in the past 5 years IBS had a positive operating cash flow.
IBS.LS Yearly Net Income VS EBIT VS OCF VS FCFIBS.LS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

1.2 Ratios

With a Return On Assets value of 1.51%, IBS perfoms like the industry average, outperforming 48.08% of the companies in the same industry.
IBS has a Return On Equity (3.42%) which is in line with its industry peers.
IBS has a Return On Invested Capital (3.81%) which is comparable to the rest of the industry.
IBS had an Average Return On Invested Capital over the past 3 years of 3.32%. This is significantly below the industry average of 10.35%.
The 3 year average ROIC (3.32%) for IBS is below the current ROIC(3.81%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 1.51%
ROE 3.42%
ROIC 3.81%
ROA(3y)9.49%
ROA(5y)5.17%
ROE(3y)16.68%
ROE(5y)5.68%
ROIC(3y)3.32%
ROIC(5y)N/A
IBS.LS Yearly ROA, ROE, ROICIBS.LS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40

1.3 Margins

The Profit Margin of IBS (2.07%) is comparable to the rest of the industry.
IBS's Profit Margin has declined in the last couple of years.
With a Operating Margin value of 5.03%, IBS perfoms like the industry average, outperforming 44.23% of the companies in the same industry.
In the last couple of years the Operating Margin of IBS has declined.
The Gross Margin of IBS (50.98%) is comparable to the rest of the industry.
IBS's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 5.03%
PM (TTM) 2.07%
GM 50.98%
OM growth 3Y-40.02%
OM growth 5Y-6.76%
PM growth 3Y-42.54%
PM growth 5Y-4.22%
GM growth 3Y-0.29%
GM growth 5Y-0.28%
IBS.LS Yearly Profit, Operating, Gross MarginsIBS.LS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60

More info and screens

3

2. Health

2.1 Basic Checks

IBS has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
Compared to 1 year ago, IBS has less shares outstanding
The number of shares outstanding for IBS has been increased compared to 5 years ago.
Compared to 1 year ago, IBS has a worse debt to assets ratio.
IBS.LS Yearly Shares OutstandingIBS.LS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
IBS.LS Yearly Total Debt VS Total AssetsIBS.LS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

IBS has an Altman-Z score of 2.01. This is not the best score and indicates that IBS is in the grey zone with still only limited risk for bankruptcy at the moment.
With a Altman-Z score value of 2.01, IBS perfoms like the industry average, outperforming 57.69% of the companies in the same industry.
IBS has a debt to FCF ratio of 4.26. This is a neutral value as IBS would need 4.26 years to pay back of all of its debts.
IBS's Debt to FCF ratio of 4.26 is fine compared to the rest of the industry. IBS outperforms 73.08% of its industry peers.
A Debt/Equity ratio of 0.71 indicates that IBS is somewhat dependend on debt financing.
IBS has a Debt to Equity ratio of 0.71. This is in the better half of the industry: IBS outperforms 63.46% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.71
Debt/FCF 4.26
Altman-Z 2.01
ROIC/WACC0.61
WACC6.21%
IBS.LS Yearly LT Debt VS Equity VS FCFIBS.LS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M 400M

2.3 Liquidity

A Current Ratio of 0.96 indicates that IBS may have some problems paying its short term obligations.
IBS has a Current ratio (0.96) which is in line with its industry peers.
IBS has a Quick Ratio of 0.96. This is a bad value and indicates that IBS is not financially healthy enough and could expect problems in meeting its short term obligations.
IBS has a Quick ratio (0.87) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 0.96
Quick Ratio 0.87
IBS.LS Yearly Current Assets VS Current LiabilitesIBS.LS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

4

3. Growth

3.1 Past

The earnings per share for IBS have decreased strongly by -30.51% in the last year.
The Earnings Per Share has been decreasing by -8.23% on average over the past years.
Looking at the last year, IBS shows a quite strong growth in Revenue. The Revenue has grown by 17.65% in the last year.
IBS shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -0.46% yearly.
EPS 1Y (TTM)-30.51%
EPS 3Y-29.2%
EPS 5Y-8.23%
EPS Q2Q%100%
Revenue 1Y (TTM)17.65%
Revenue growth 3Y32.48%
Revenue growth 5Y-0.46%
Sales Q2Q%18.09%

3.2 Future

The Earnings Per Share is expected to grow by 18.23% on average over the next years. This is quite good.
Based on estimates for the next years, IBS will show a small growth in Revenue. The Revenue will grow by 6.79% on average per year.
EPS Next Y-16.54%
EPS Next 2Y15.36%
EPS Next 3Y20.34%
EPS Next 5Y18.23%
Revenue Next Year15.39%
Revenue Next 2Y9.99%
Revenue Next 3Y8.52%
Revenue Next 5Y6.79%

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
IBS.LS Yearly Revenue VS EstimatesIBS.LS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 200M 400M 600M
IBS.LS Yearly EPS VS EstimatesIBS.LS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 0.5 -0.5 -1

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 38.85, the valuation of IBS can be described as expensive.
IBS's Price/Earnings ratio is in line with the industry average.
IBS is valuated rather expensively when we compare the Price/Earnings ratio to 27.86, which is the current average of the S&P500 Index.
With a Price/Forward Earnings ratio of 23.67, IBS is valued on the expensive side.
The rest of the industry has a similar Price/Forward Earnings ratio as IBS.
The average S&P500 Price/Forward Earnings ratio is at 23.32. IBS is around the same levels.
Industry RankSector Rank
PE 38.85
Fwd PE 23.67
IBS.LS Price Earnings VS Forward Price EarningsIBS.LS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

Compared to the rest of the industry, the Price/Free Cash Flow ratio of IBS indicates a somewhat cheap valuation: IBS is cheaper than 78.85% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 5.92
EV/EBITDA N/A
IBS.LS Per share dataIBS.LS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6 8 10

4.3 Compensation for Growth

IBS's earnings are expected to grow with 20.34% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.36%
EPS Next 3Y20.34%

More info and screens

6

5. Dividend

5.1 Amount

With a Yearly Dividend Yield of 10.02%, IBS is a good candidate for dividend investing.
IBS's Dividend Yield is rather good when compared to the industry average which is at 3.05. IBS pays more dividend than 100.00% of the companies in the same industry.
IBS's Dividend Yield is rather good when compared to the S&P500 average which is at 2.41.
Industry RankSector Rank
Dividend Yield 10.02%

5.2 History

The dividend of IBS is nicely growing with an annual growth rate of 48.65%!
Dividend Growth(5Y)48.65%
Div Incr Years0
Div Non Decr Years0
IBS.LS Yearly Dividends per shareIBS.LS Yearly Dividends per shareYearly Dividends per share 2019 2022 2023 2024 2025 0.2 0.4 0.6 0.8 1

5.3 Sustainability

IBS pays out 268.99% of its income as dividend. This is not a sustainable payout ratio.
The dividend of IBS is growing, but the earnings are growing slower. This means the dividend growth is not sustainable.
DP268.99%
EPS Next 2Y15.36%
EPS Next 3Y20.34%
IBS.LS Yearly Income VS Free CF VS DividendIBS.LS Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M
IBS.LS Dividend Payout.IBS.LS Dividend Payout, showing the Payout Ratio.IBS.LS Dividend Payout.PayoutRetained Earnings

More info and screens

IBERSOL SGPS SA

ELI:IBS (10/3/2025, 7:00:00 PM)

10.1

0 (0%)

Chartmill FA Rating
GICS IndustryGroupConsumer Services
GICS IndustryHotels, Restaurants & Leisure
Earnings (Last)09-12 2025-09-12/amc
Earnings (Next)11-27 2025-11-27
Inst Owners21.88%
Inst Owner ChangeN/A
Ins Owners0.03%
Ins Owner ChangeN/A
Market Cap419.25M
Analysts83.33
Price Target11.82 (17.03%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 10.02%
Yearly Dividend0.49
Dividend Growth(5Y)48.65%
DP268.99%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)5.24%
Min Revenue beat(2)-0.81%
Max Revenue beat(2)11.28%
Revenue beat(4)3
Avg Revenue beat(4)8.29%
Min Revenue beat(4)-0.81%
Max Revenue beat(4)12.41%
Revenue beat(8)7
Avg Revenue beat(8)6.42%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-11.21%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-72.41%
EPS NY rev (1m)0%
EPS NY rev (3m)-36.9%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)18.9%
Revenue NY rev (1m)0%
Revenue NY rev (3m)7.7%
Valuation
Industry RankSector Rank
PE 38.85
Fwd PE 23.67
P/S 0.82
P/FCF 5.92
P/OCF 3.6
P/B 1.35
P/tB 1.98
EV/EBITDA N/A
EPS(TTM)0.26
EY2.57%
EPS(NY)0.43
Fwd EY4.23%
FCF(TTM)1.71
FCFY16.9%
OCF(TTM)2.81
OCFY27.81%
SpS12.33
BVpS7.47
TBVpS5.09
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 1.51%
ROE 3.42%
ROCE 4.85%
ROIC 3.81%
ROICexc 4.93%
ROICexgc 6.48%
OM 5.03%
PM (TTM) 2.07%
GM 50.98%
FCFM 13.85%
ROA(3y)9.49%
ROA(5y)5.17%
ROE(3y)16.68%
ROE(5y)5.68%
ROIC(3y)3.32%
ROIC(5y)N/A
ROICexc(3y)5.24%
ROICexc(5y)N/A
ROICexgc(3y)7.05%
ROICexgc(5y)N/A
ROCE(3y)4.21%
ROCE(5y)N/A
ROICexcg growth 3Y-24.94%
ROICexcg growth 5Y-3.32%
ROICexc growth 3Y-22.88%
ROICexc growth 5Y-3.24%
OM growth 3Y-40.02%
OM growth 5Y-6.76%
PM growth 3Y-42.54%
PM growth 5Y-4.22%
GM growth 3Y-0.29%
GM growth 5Y-0.28%
F-Score6
Asset Turnover0.73
Health
Industry RankSector Rank
Debt/Equity 0.71
Debt/FCF 4.26
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales 8.93%
Interest Coverage 250
Cash Conversion N/A
Profit Quality 667.98%
Current Ratio 0.96
Quick Ratio 0.87
Altman-Z 2.01
F-Score6
WACC6.21%
ROIC/WACC0.61
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)9.76%
Cap/Sales(5y)11.65%
Profit Quality(3y)200.89%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-30.51%
EPS 3Y-29.2%
EPS 5Y-8.23%
EPS Q2Q%100%
EPS Next Y-16.54%
EPS Next 2Y15.36%
EPS Next 3Y20.34%
EPS Next 5Y18.23%
Revenue 1Y (TTM)17.65%
Revenue growth 3Y32.48%
Revenue growth 5Y-0.46%
Sales Q2Q%18.09%
Revenue Next Year15.39%
Revenue Next 2Y9.99%
Revenue Next 3Y8.52%
Revenue Next 5Y6.79%
EBIT growth 1Y19.24%
EBIT growth 3Y-20.54%
EBIT growth 5Y-7.19%
EBIT Next Year434.69%
EBIT Next 3Y84.16%
EBIT Next 5Y57.35%
FCF growth 1Y26.38%
FCF growth 3Y-0.14%
FCF growth 5Y-9.32%
OCF growth 1Y23.94%
OCF growth 3Y1.82%
OCF growth 5Y-6.35%